Project Grant R01HL180328
Award Date 9/20/25
Completion Date 6/30/30
Dollars Obligated $787K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Palo Alto, CA 94304, USA
Similar Awards
- This Project Grant award of $395,314 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The Leland Stanford Junior University aims to define the key cellular components and early immunologic events that mediate factor VIII immunity in persons with hemophilia A. The research will investigate the role of type 2 conventional dendritic cells (CDC2) in the development of anti-factor VIII antibodies, with the long-term goal of developing targeted...
- This Project Grant award of $234,750.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to examine the immunological mechanisms that initiate and orchestrate the development of anti-factor VIII alloantibodies, known as inhibitors, in patients with severe hemophilia A. The research is being conducted by Emory University and seeks to identify key immune pathways and risk factors that predict the likelihood of inhibitor development, with the goal...
- This $662,949 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) is supporting the development of innovative cell and gene therapy strategies to treat Fanconi anemia (FA), a leading cause of inherited bone marrow failure. The award to The Leland Stanford Junior University aims to establish stable hematopoiesis in FA patients without the use of genotoxic chemotherapy or irradiation. Key objectives include generating targeted...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $410,449 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The Leland Stanford Junior University (Stanford University) on August 1, 2025. The funding supports research to develop novel synthetic biology strategies that would enable the quantitative and dynamic regulation of growth factors and cytokines produced from human induced pluripotent stem cell-derived endothelial cells (iPSC-ECs). The goal...
- This Project Grant award of $636,982.00 was provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to comprehensively investigate the proteolytic mechanisms that govern factor VIII regulation before and after activation, which is critical for maintaining normal blood clotting and preventing bleeding disorders like hemophilia A. The project aims to understand how proteolysis of factor...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $162,486 to The Leland Stanford Junior University to engineer hematopoietic stem cells to produce B cells that secrete antibodies against PCSK9, a promising treatment for hypercholesterolemia. The research aims to develop a durable, lifelong therapeutic solution by using CRISPR/Cas9 genome editing to target an engineered antibody transgene into a safe-harbor site in...
- The National Heart Lung and Blood Institute (NHLBI), through the Cardiovascular Diseases Research grant program (CFDA 93.837), awarded a $128,085 project grant to The Leland Stanford Junior University (Stanford University) to investigate the role of the COUP-TFII transcription factor in human vein development. The research aims to establish whether COUP-TFII is required for human vein endothelial cell specification and identify the specific protein domains of COUP-TFII involved. The project...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $161,903 Project Grant to The Leland Stanford Junior University (Stanford University) on January 31, 2025 under the Cardiovascular Diseases Research (CFDA 93.837) program. The project aims to investigate risk stratification and outcomes across the spectrum of immune checkpoint inhibitor (ICI) cardiotoxicity subtypes. Specifically, the study will: (1) retrospectively examine cardiac and oncologic outcomes associated with ICI...
- This Project Grant award of $705,405 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The Leland Stanford Junior University supports research focused on characterizing the role of adventitial fibroblasts in atherosclerosis. The research aims to identify new therapeutic targets and pathways related to this understudied cell population's influence on atherosclerotic plaque formation and calcification. The project will leverage single-cell genomics,...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $131,211 to The Leland Stanford Junior University to conduct research on high-resolution tracking of T cell differentiation to predict and control alloreactive disease in allogeneic hematopoietic stem cell transplantation (allo-HSCT). The grant, which has a performance period from July 15, 2025 to June 30, 2027, aims to identify alloreactive T cell subsets...